Unresectable or Metastatic Myxofibrosarcoma: Second-Line Treatment When Anthracycline-Based Therapy Has Failed

Clinical Scenario

This protocol applies to patients with unresectable locally advanced or metastatic myxofibrosarcoma — a stage associated with a very poor prognosis — who have already received first-line anthracycline-based systemic therapy without achieving an adequate response.

Previous Line — Escalation Trigger

First-line treatment with anthracycline with or without ifosfamide did not meet the required goal of partial tumor response on imaging.

Insufficient radiological response → escalate to next line

Next-Line Approach (Partial Overview)

After failure of anthracycline-based therapy, the next-line strategy draws on multiple classes of systemic treatment — including chemotherapy agents, an oral targeted agent, and immunotherapy options.

The clinical objective is partial or complete tumor response on imaging. Full regimen options, eligibility criteria, and sequencing are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/diagnostics13193022

The development of unresectable locally advanced or metastatic MFS is assocaited with a very poor prognosis.

Gemcitabine can be used as a monotherapy or in combination with docetaxel or dacarbazine in pretreated STS patients.

Although the exact role of gemcitabine remains unclear, gemcitabine-based therapy can be an effective option for metastatic MFS patients.

Trabectedin can be administered effectively and safely to patients with advanced STS at second- or later-line setting.

Japan is the only country where eribulin is approved for all types of STS, including non-L-sarcomas such as MFS and UPS.

Pazopanib is an oral multitargeted tyrosine kinase inhibitor (TKI) with anti-angiogenic and anti-tumorigenic properties and it has been approved in multiple countries as a second- or later-line treatment for patients with advanced non-adipocytic STS.

In a single-arm open-label multicenter phase 2 trial (SARC028), pembrolizumab (anti-PD-1 antibody) provided an objective response rate (ORR) of 18% in the STS cohort.

In a randomized open-label non-comparative multicenter phase 2 trial (Alliance A091401), 85 patients with metastatic sarcoma received either nivolumab alone or nivolumab in combination with ipilimumab (anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody).

A radiological PR or complete response (CR) was observed in four (57%) of the seven patients.

View source ↗